hiv
envelop
glycoprotein
env
bind
cell
surfaceassoci
receptor
coreceptor
one
two
noncoval
associ
subunit
induc
conform
chang
activ
subunit
caus
fusion
viral
plasma
cell
membran
result
deliveri
viral
genom
cell
prabakaran
et
al
ligand
bs
bs
mab
unligand
mab
b
figur
molecular
surfac
diagram
unligand
ligand
b
core
render
view
perspect
receptor
bind
residu
direct
contact
blue
residu
contact
antibodi
name
red
contact
residu
select
limit
interatom
distanc
core
antibodi
prabakaran
et
al
initi
infect
cycl
hiv
protein
expos
environ
env
also
major
immunogen
neutral
antibodi
direct
target
rel
easi
access
inhibitor
fundament
problem
develop
effect
vaccin
inhibitor
hiv
rapid
gener
alter
high
level
express
long
chronic
infect
result
signific
heterogen
env
preserv
env
function
entri
mediat
limit
size
express
impos
restrict
variabl
lead
exist
conserv
structur
chapter
discuss
advanc
understand
env
structur
relat
interact
conserv
env
structur
receptor
molecul
antibodi
implic
design
vaccin
immunogen
inhibitor
viral
membraneassoci
glycoprotein
divers
function
life
cycl
envelop
viru
dimitrov
smith
heleniu
attach
virion
cell
bind
host
cell
receptor
mediat
membran
fusion
subsequ
step
viru
entri
direct
progeni
virion
morphogenesi
bud
case
receptordestroy
enzymat
activ
virion
releas
prevent
superinfect
hiv
except
envelop
glycoprotein
env
serv
least
two
function
critic
hiv
replic
cyclebind
receptor
coreceptor
use
one
two
noncoval
associ
subunit
fuse
viral
plasma
cell
membran
mediat
subunit
also
major
antigen
immunogen
known
neutral
antibodi
direct
chapter
focu
advanc
knowledg
env
structur
function
relat
interact
coreceptor
neutral
antibodi
emphas
conserv
env
structur
element
could
use
design
vaccin
immunogen
inhibitor
number
excel
review
publish
provid
detail
variou
aspect
env
serv
sourc
addit
citat
broder
dimitrov
burton
montefiori
burton
et
al
dimitrov
broder
douek
et
al
fox
et
al
freedman
et
al
gallo
et
al
hunter
iii
structur
env
like
mani
viral
envelop
glycoprotein
hiv
env
consist
two
subunit
surfac
glycoprotein
su
respons
bind
receptor
molecul
transmembran
glycoprotein
tm
mediat
fusion
viral
membran
plasma
cell
membran
initi
synthes
nonfusogen
polyprotein
precursor
env
cleav
host
cell
proteas
furin
su
tm
subunit
remain
noncoval
associ
refer
complex
also
use
interchang
abbrevi
env
design
function
fusogen
hiv
envelop
glycoprotein
like
viral
envelop
glycoprotein
env
oligomer
current
accept
view
trimer
heterodim
consist
heavili
glycosyl
result
rel
high
molecular
weight
kda
monom
half
mass
due
carbohydr
monomer
env
molecul
consist
amino
acid
depend
isol
residu
belong
sequenc
analysi
variou
isol
suggest
exist
five
rel
conserv
region
five
region
significantli
higher
sequenc
variabilityup
fig
myer
et
al
starcich
et
al
four
variabl
region
disulfid
bridg
two
end
tm
glycoprotein
conserv
su
protein
commonli
case
viral
envelop
glycoprotein
like
relat
major
role
fusion
viral
cell
membran
includ
fusion
domain
fd
also
known
fusion
peptid
consist
hydrophob
stretch
amino
acid
residu
nterminu
two
heptad
repeat
transmembran
domain
tm
three
stretch
residu
four
major
region
cytoplasm
tail
fd
heptad
repeat
tm
highli
conserv
total
number
potenti
glycosyl
site
function
vari
close
extent
conserv
site
also
variabl
glycosyl
site
conserv
primari
structur
featur
env
approxim
amino
acid
number
summar
fig
phylogenet
analysi
envelop
sequenc
reveal
exist
cluster
approxim
equidist
one
anoth
name
clade
subtyp
initi
six
clade
af
prototyp
northamericaneuropean
strain
relabel
subtyp
b
found
hiv
envelop
glycoprotein
myer
et
al
five
six
envbas
subtypesclad
b
c
f
subtyp
e
design
circul
recombin
form
also
identifi
gag
gene
louwagi
et
al
base
phylogenet
comparison
partial
sequenc
subtyp
g
j
ad
janssen
et
al
leitner
et
al
subtyp
togeth
design
group
call
stand
main
distinguish
group
outlier
gurtler
et
al
n
nonm
nono
simon
et
al
figur
show
phylogenet
relationship
among
group
member
tree
construct
use
group
consensu
sequenc
download
hiv
sequenc
databas
august
http
wwwhivlanlgov
demonstr
sequenc
variat
env
sampl
env
sequenc
subtyp
b
c
obtain
hiv
sequenc
databas
align
amino
acid
variabl
posit
calcul
fig
note
although
level
variat
high
variabl
region
region
env
rel
conserv
case
contain
invari
residu
tempt
specul
region
close
conserv
import
function
target
antibodi
small
molecul
drug
may
mutat
without
signific
loss
fit
viru
env
sequenc
use
predict
secondari
structur
comput
model
perhap
popular
model
develop
gallah
et
al
gallah
et
al
env
threedimension
structur
avail
model
predict
predominantli
helic
structur
later
crystal
structur
analysi
reveal
mostli
bsheet
structur
howev
model
correctli
predict
essenti
featur
specif
two
heptad
repeat
form
helic
structur
model
use
lack
avail
structur
nativ
addit
predict
local
subtyp
b
c
xax
indic
posit
amino
acid
well
allow
gap
multipl
sequenc
align
yax
denot
valu
sequenc
variat
posit
variabl
loop
appar
larger
sequenc
variat
compar
portion
env
see
text
hiv
envelop
glycoprotein
heptad
repeat
also
use
applic
includ
local
antibodi
epitop
determin
crystal
structur
deglycosyl
core
iiib
complex
twodomain
fragment
fab
fig
c
resolut
kwong
et
al
major
breakthrough
still
paradigm
research
env
structur
function
later
resolut
improv
structur
core
anoth
primari
isol
solv
kwong
et
al
structur
variabl
region
avail
recent
crystal
structur
jrfl
core
determin
complex
broadli
neutral
antibodi
fab
resolut
fig
huang
et
al
fulli
glycosyl
unligand
core
structur
siv
isol
also
recent
solv
despit
resolutionlimit
problem
fig
structur
detail
deriv
four
publish
crystal
structur
provid
wealth
inform
interact
receptor
antibodi
describ
detail
complex
antibodi
uniqu
fold
compris
two
domain
inner
outer
design
respect
locat
nand
ctermini
bridg
fourstrand
antiparallel
sheet
fig
inner
domain
contain
two
helic
small
fivestrand
bsandwich
outer
domain
consist
sixstrand
mixeddirect
bsheet
clamp
helix
sevenstrand
antiparallel
bbarrel
locat
stem
near
inner
domain
appear
stem
differ
region
outer
domain
surfac
recent
solv
structur
suggest
structur
protrud
nm
core
toward
target
membran
fig
huang
et
al
core
structur
three
differ
isol
iiib
jrfl
complex
two
differ
antibodi
essenti
suggest
lack
conform
chang
induc
antibodi
also
core
structur
preserv
three
isol
addit
sinc
seven
disulfid
bridg
core
conserv
buri
one
expect
major
featur
core
exist
inner
outer
domain
join
bridg
sheet
well
variou
structur
element
includ
predominantli
btype
structur
element
would
preserv
hiv
isol
sequenc
compris
inner
domain
rel
conserv
outer
domain
topolog
structur
found
compat
result
biochem
studi
howev
uniqu
twodomain
arrang
link
figur
crystal
structur
core
unligand
ligand
state
ribbon
diagram
unligand
siv
core
shown
orient
ligand
hiv
structur
color
code
rainbow
represent
color
blue
red
nto
cterminu
posit
variabl
loop
bridg
sheet
label
b
ribbon
diagram
depict
hiv
core
complex
first
two
domain
receptor
fab
fragment
human
monoclon
neutral
antibodi
shown
outer
domain
green
yellow
ligand
unligand
rel
conserv
dramat
chang
inner
domain
blue
cyan
occur
bridg
sheet
connect
inner
outer
domain
form
unligand
bridg
sheet
allow
larg
receptorinduc
conform
chang
anticip
unligand
free
structur
arrang
remark
differ
form
fig
bind
induc
larg
structur
chang
inner
domain
although
overal
inner
domain
structur
unligand
differ
structur
element
secondari
structur
preserv
significantli
shuffl
reorgan
inde
contrast
ligand
state
inner
domain
unligand
state
singl
domain
mixer
distinct
substructuresan
ahelix
bribbon
structur
complex
receptor
antibodi
core
green
bound
orang
fab
antibodi
magenta
heavi
pink
light
chain
b
cdr
conform
antibodi
free
bound
form
given
stereoview
crystal
structur
antibodi
avail
isol
pdb
code
respect
c
core
intact
green
bound
orang
fab
antibodi
blue
heavi
cyan
light
chain
cdr
loop
label
indic
arrow
cdr
conform
antibodi
c
similar
free
bound
form
notabl
undergo
larg
conform
chang
maximum
displac
blue
bound
form
light
blue
free
form
hiv
envelop
glycoprotein
one
half
bridg
sheet
stem
threestrand
bsheet
two
consecut
strand
fig
four
conserv
disulfid
bond
inner
domain
could
interlock
structur
element
allow
larg
motion
respect
contrast
inner
domain
outer
domain
structur
chang
significantli
bind
except
local
variat
shown
segment
color
green
yellow
fig
promin
featur
unligand
structur
bridg
sheet
absent
two
bribbon
displac
two
major
differ
unligand
ligand
structur
relat
bind
first
disloc
loop
conserv
ggdpe
sequenc
motif
contact
complementar
determin
region
cdr
loop
second
reorient
loop
form
bribbon
bridg
sheet
addit
receptor
coreceptor
bind
site
form
unligand
conform
fig
structur
nativ
state
complex
current
unknown
howev
sever
structur
fragment
solv
like
correspond
postreceptorbind
state
crystal
structur
selfassembl
chan
et
al
weissenhorn
et
al
siv
malashkevich
et
al
heptad
repeat
reveal
sixhelix
coiledcoil
bundl
fig
coiledcoil
structur
featur
previous
note
hemagglutinin
membran
span
subunit
bullough
et
al
carr
kim
tm
subunit
moloney
murin
leukemia
viru
momlv
fass
et
al
heptad
repeat
amino
acid
residu
long
hydrophob
repeat
sequenc
locat
fusion
transmembran
domain
fig
complex
peptid
base
heptad
repeat
lead
format
thermodynam
stabl
core
core
complex
sixstrand
helic
bundl
structur
consist
intern
trimer
coil
coil
three
helic
run
parallel
extern
shell
three
helic
run
antiparallel
helic
lefthand
manner
around
central
coiledcoil
trimer
fig
overal
size
complex
rectangular
shape
width
height
fragment
connect
thought
highli
flexibl
conserv
pattern
amino
acid
residu
heptad
region
correl
structur
function
properti
ahel
core
structur
npeptid
amino
acid
residu
make
proteinprotein
interact
intern
trimer
form
groov
surfac
interact
cpeptid
thu
npeptid
residu
involv
interact
highli
conserv
among
siv
similarli
cpeptid
residu
interact
npeptid
helic
conserv
broad
rang
isol
key
structur
featur
surfac
trimer
deep
larg
caviti
made
result
hydrophob
pocket
pocket
accommod
three
protrud
hydrophob
residu
helix
residu
form
caviti
ident
siv
strain
structur
provid
use
inform
membran
fusion
mechan
well
possibl
inhibit
mutat
residu
respons
core
stabil
affect
hiv
infect
membran
fusion
posit
key
mutat
map
interact
site
helic
oligomer
structur
env
critic
understand
mechan
entri
neutral
structur
remain
unknown
hope
progress
near
futur
recent
cryoelectron
microscopi
cem
provid
glimps
oligomer
env
may
look
like
although
atom
level
detail
two
differ
studi
depict
somewhat
differ
trimer
env
analyz
distribut
virion
surfac
fig
zanetti
et
al
zhu
et
al
zhu
et
al
describ
structur
detail
siv
virion
resolut
individu
env
three
monom
tripodlik
structur
overal
structur
env
two
compon
head
stalk
head
mainli
compos
support
stalk
form
three
separ
leg
dimens
trimer
env
deriv
studi
nm
thick
head
nm
vertic
length
leg
compar
deriv
earlier
studi
zhu
et
al
open
tripodlik
leg
arrang
also
seen
env
momlv
forster
et
al
oneleg
env
head
leg
compact
stalk
head
b
figur
diagram
illustr
structur
env
spike
reveal
cryoelectron
microscopi
model
obtain
resolut
zhu
et
al
head
structur
compris
trimer
three
lobe
support
three
separ
leg
tripodlik
arrang
model
fit
base
avail
crystal
structur
suggest
carbohydr
top
peripheri
appear
closer
variabl
loop
may
shield
conserv
region
b
env
spike
model
resolut
present
zanetti
et
al
similar
threelob
head
support
stalk
seen
zhu
et
al
subtli
differ
compact
stalk
obviou
separ
three
leg
stem
model
fit
use
core
structur
indic
expos
receptor
bind
site
protect
sugar
variabl
loop
bridg
sheet
either
hidden
interfac
protect
loop
leg
consider
separ
potenti
access
antibodi
use
core
structur
ligand
unligand
state
zhu
et
al
perform
dock
tomogram
appear
top
sugarco
face
variabl
loop
along
side
spike
mask
critic
site
transmembran
glycoprotein
side
lower
densiti
observ
leg
stem
region
highli
conserv
membran
proxim
extern
region
mper
locat
caus
gap
surfacerend
model
suggest
possibl
interact
region
plasma
membran
recent
cem
studi
zanetti
et
al
also
focus
tomograph
env
structur
siv
studi
also
reveal
env
organ
threelob
membranedist
trimer
tightli
interact
monom
trimer
lead
mushroomshap
structur
singl
stalk
latter
arrang
env
singl
leg
contradict
tripod
leg
seen
zhu
et
al
possibl
reason
discrep
model
could
due
differ
data
collect
imag
analysi
strategi
employ
subramaniam
appear
cem
imag
still
development
stage
refin
methodolog
need
result
promis
technolog
could
accept
confid
howev
model
provid
new
level
structur
knowledg
understand
nativ
trimer
env
conform
advanc
cem
imag
xray
crystallographi
higher
resolut
analyz
env
complex
differ
monoclon
antibodi
mab
recogn
variou
segment
env
could
provid
accur
complet
inform
enter
cell
hiv
interact
receptor
molecul
although
formal
demonstr
coreceptor
suffici
mediat
membran
fusion
bind
env
exampl
incorpor
bilay
membran
show
fusion
appear
major
determin
effici
kinet
plasma
cell
membran
fusion
hiv
dalgleish
et
al
feng
et
al
klatzmann
et
al
altern
receptor
notabl
galactosyl
ceramid
could
mediat
fusion
cell
low
effici
biolog
relev
clear
alfsen
bomsel
harous
et
al
kensing
et
al
similarli
major
biolog
import
coreceptor
although
chemokin
receptor
also
serv
coreceptor
puffer
et
al
sharron
et
al
number
molecul
found
could
enhanc
fusion
process
mostli
enhanc
bind
hiv
envelop
glycoprotein
directli
involv
entri
process
broder
dimitrov
pleskoff
et
al
thu
review
advanc
understand
env
interact
coreceptor
critic
hiv
entri
cell
focu
mostli
structur
basi
interact
human
kda
type
membran
glycoprotein
consist
amino
acid
deriv
cdna
sequenc
littman
et
al
maddon
et
al
contain
extracellular
portion
link
hydrophob
transmembran
domain
cytoplasm
tail
extracellular
portion
divid
four
immunoglobulin
ig
like
domain
design
everi
domain
except
contain
one
disulfid
bridg
glycosyl
two
nlink
glycosyl
site
overal
shape
extracellular
portion
rodlik
length
nm
transmembran
portion
rich
hydrophob
amino
acid
residu
form
helic
structur
short
cytoplasm
tail
associ
lck
tyrosin
kinas
src
famili
contain
two
cystein
essenti
interact
lck
crystal
structur
first
two
domain
first
solv
human
wang
et
al
structur
membran
proxim
domain
later
solv
rat
lang
et
al
final
crystal
structur
whole
extracellular
portion
fourdomain
also
known
solubl
solv
wu
et
al
fragment
form
rigid
rodlik
similar
structur
area
buri
domain
allow
limit
flexibl
first
domain
contain
highaffin
bind
site
compos
nine
bstrand
follow
ig
fold
resembl
mani
aspect
structur
variabl
v
domain
ig
analog
antibodi
v
domain
nine
strand
term
b
c
c
c
e
f
g
four
abd
form
antiparallel
bsheet
pack
anoth
antiparallel
bsheet
form
cc
c
fg
also
analog
hypervari
cdr
ig
v
domain
loop
strand
b
c
term
c
c
term
f
g
term
howev
two
import
differ
ig
v
domain
miss
featur
ig
domain
involv
dimer
anoth
v
domain
c
c
loop
protrud
away
bodi
domain
particularli
hydrophob
side
chain
complet
expos
water
exposur
play
import
role
interact
domain
signific
overlap
stabil
conform
fragment
make
signific
motion
joint
region
unlik
structur
fragment
third
fourth
domain
rat
resembl
human
fragment
crystal
structur
fourdomain
molecul
suggest
hing
region
second
third
domain
produc
variabl
structur
suggest
flexibl
also
found
form
dimer
dimer
occur
interact
domain
solut
dimer
occur
rel
high
concentr
millimolar
rang
indic
rel
weak
interact
explain
dimer
observ
gel
howev
membran
surfac
due
limit
motion
restrict
relat
domain
structur
membran
local
concentr
could
rel
high
lead
format
dimer
simpl
estim
show
typic
lymphocyt
radiu
sever
micromet
membran
thick
nm
surfaceassoci
molecul
equival
bulk
concentr
millimolar
rang
earlier
observ
base
later
mobil
measur
demonstr
larg
portion
membraneassoci
dimer
form
higher
order
complex
pal
et
al
biolog
function
first
studi
rat
lymphocyt
identifi
use
william
et
al
human
homologu
identifi
human
cell
use
mab
reinherz
et
al
express
peripher
blood
lymphocyt
reinherz
et
al
cell
monocytemacrophag
lineag
includ
microgli
cell
dendrit
cell
antigenpres
cell
includ
langerhan
cell
skin
mucou
membran
play
central
role
initi
cell
respons
coreceptor
antigendepend
class
ii
major
histocompat
complex
mhc
depend
interact
initi
tcell
activ
tcell
receptor
tcr
reinherz
schlossmann
accord
coreceptor
model
tcr
bind
class
ii
molecul
physic
associ
cell
surfac
antigen
stimul
complex
gener
much
stronger
signal
tcr
alon
molecul
transduc
signal
addit
central
role
activ
helper
cell
may
physiolog
function
exampl
interact
lead
increas
intracytoplasm
calcium
inositol
trisphosph
migratori
respons
bind
rel
high
nm
affin
highli
variabl
isol
test
significantli
depend
temperatur
suggest
bind
entropi
determin
kinet
hiv
envelop
glycoprotein
constant
bind
express
cell
depend
temperatur
suggest
exist
energi
barrier
associ
rate
constant
c
determin
respect
dissoci
rate
dimitrov
et
al
associ
rate
constant
decreas
temperatur
follow
doubl
hyperbol
depend
break
c
c
associ
constant
valu
reach
decreas
comparison
valu
c
equilibrium
dissoci
constant
rate
constant
vari
differ
experiment
system
use
measur
thembind
express
cell
virion
bind
express
cell
solut
thu
reflect
chang
structur
env
differ
viru
isol
effect
oligomer
structur
essenti
featur
bind
process
remain
consist
bind
two
larg
molecul
bind
site
area
much
smaller
overal
surfac
area
moleculessimilar
bind
antibodi
larg
antigen
bind
site
dissect
use
mab
specif
differ
epitop
sitedirect
mutagenesi
local
first
domainamino
acid
xray
crystallographi
data
show
bind
epitop
ridgelik
structur
form
c
c
strand
loop
connect
correspond
ig
v
domain
top
c
hydrophob
amino
acid
complet
expos
water
environ
critic
bind
exposur
suggest
contain
hydrophob
cleft
abl
accommod
protrud
xray
crystal
structur
resolut
core
complex
twodomain
fragment
human
antigenbind
fragment
antibodi
block
chemokinereceptor
bind
reveal
cavityladen
interfac
conserv
bind
site
chemokin
receptor
evid
conform
chang
bind
natur
antibodi
epitop
specif
mechan
immun
evas
kwong
et
al
accur
model
lesswellord
region
provid
conclus
identif
densiti
central
caviti
crux
interact
structur
core
primari
clinic
isol
compar
show
bind
rigid
portion
core
conform
flexibl
overal
differ
minor
sequenc
chang
concentr
surfac
expect
expos
envelop
oligom
kwong
et
al
ongo
crystallograph
studi
reveal
conserv
region
involv
bind
target
broadli
neutral
antibodi
conceal
immun
recognit
kwong
bind
induc
rearrang
complex
result
two
type
structur
chang
dissoci
complex
shed
exposur
epitop
measur
increas
antibodi
bind
enhanc
cleavag
proteas
lack
correl
shed
membran
fusion
argu
shed
fusion
intermedi
possibl
remain
shed
repres
either
abort
pathway
fusion
final
product
interact
despit
lack
knowledg
shed
involv
fusion
clear
contribut
irrevers
inactiv
well
neutral
antibodi
result
recent
studi
indic
interact
membraneassoci
oligomer
env
cluster
membraneassoci
induc
conform
chang
interact
coreceptor
result
exposur
helic
structur
reactiv
antibodi
exampl
parallel
reaction
envtarget
complex
dissoci
expos
trigger
surfac
dissoci
monom
inactiv
mani
cell
neural
epitheli
cervic
fibroblast
origin
infect
hiv
includ
primari
viru
isol
case
infect
still
mediat
low
undetect
amount
mani
system
mab
exampl
well
inhibit
infect
even
high
concentr
clearli
demonstr
infect
mediat
molecul
one
molecul
implic
mediat
infect
particularli
neural
colon
epitheli
possibl
sperm
cell
galactosyl
ceramid
deriv
structur
homologu
molecul
monohexosid
glycolipid
insert
cellular
plasma
membran
two
aliphat
chain
ceramid
moieti
contain
one
galactos
residu
bglycosid
linkag
protrud
outsid
membran
appar
bind
site
antibodi
glycolipid
propos
altern
hiv
receptor
base
inhibit
hiv
infect
antibodi
bind
galactosyl
ceramid
well
associ
greater
infect
higher
express
molecul
galactosyl
ceramid
detect
lymphoid
cell
express
monocytederiv
macrophag
mdm
antibodi
reduc
virion
bind
inhibit
infect
macrophag
unlik
infect
cell
infect
cell
usual
lower
effici
possibl
due
ineffici
altern
receptor
small
number
cell
express
background
ineffici
viru
spread
detect
inhibit
difficult
demonstr
inhibit
infect
neural
cell
line
antigalactosyl
ceramid
hiv
envelop
glycoprotein
antibodi
signific
complet
howev
infect
colon
epitheli
cell
line
antibodi
almost
complet
prevent
infect
contrast
antibodi
effect
evid
propos
role
galactosyl
ceramid
altern
receptor
come
studi
bind
cell
express
galactosyl
ceramid
deriv
bind
specif
rel
high
affinityth
equilibrium
dissoci
constant
nanomolar
rang
galactos
residu
bglycosid
linkag
like
site
bind
glycolipid
bind
receptor
accur
determin
may
requir
intact
structur
denatur
prevent
bind
galactosyl
ceramid
acid
fragment
contain
region
probabl
involv
bind
galactosyl
ceramid
shown
gener
infecti
chimer
virus
contain
fragment
lai
infect
galactosyl
ceramid
express
cell
contrast
involv
loop
also
shown
loop
antibodi
block
bind
galactosyl
ceramid
interestingli
preincub
caus
increas
bind
galactosyl
ceramid
consist
model
induc
conform
chang
lead
increas
exposur
epitop
includ
loop
whether
bind
galactosyl
ceramid
induc
conform
chang
need
clarifi
alreadi
shown
galactosyl
ceramid
mediat
entri
requir
coreceptor
least
help
altern
infect
pathway
includ
fcreceptorand
viru
uptak
pathway
effici
receptor
natur
particip
molecul
character
extens
galactosyl
ceramid
infect
gener
effici
cell
strain
abil
induc
rapidli
spread
infect
syncytia
format
cell
line
highli
cytopath
natur
infect
suggest
strain
abl
util
altern
receptor
high
effici
unlik
case
infect
galactosyl
ceramid
express
cell
demonstr
receptor
strain
term
coreceptor
tcell
line
tropic
isol
endr
et
al
strain
deriv
isol
shown
infect
number
lymphoid
cell
line
tcell
hsb
bcell
daudi
origin
well
nonlymphoid
rhabdomyosarcoma
line
rd
cell
infect
infect
rapid
extens
cytophat
format
syncyti
inhibit
antibodi
infect
serv
altern
receptor
support
three
line
evid
infect
cell
inhibit
specif
mab
cell
express
abl
fuse
cell
support
viral
infect
downregul
infect
possibl
due
direct
interact
env
env
indirect
effect
interact
involv
residu
nterminu
second
third
extracellular
loop
lin
et
al
use
coreceptor
primari
receptor
isol
indic
whether
molecul
serv
receptor
coreceptor
depend
viru
structur
anoth
demonstr
abil
hiv
rapid
accommod
chang
environ
hypothes
chemokin
receptor
could
initi
use
primari
receptor
primat
lentivirus
adapt
later
event
dimitrov
dimitrov
broder
avail
evid
suggest
biolog
import
coreceptor
hiv
chemokin
receptor
berger
et
al
consist
extracellular
nterminu
intracellular
cterminu
seven
ahel
transmembran
domain
sever
conserv
pro
residu
three
intracellular
three
extracellular
loop
compos
hydrophil
amino
acid
dimitrov
broder
dimitrov
et
al
highli
conserv
cystein
residu
form
disulfid
bond
first
second
extracellular
loop
nterminu
third
extracellular
loop
acid
long
protein
possess
highli
acid
ntermini
contain
two
potenti
nlink
glycosyl
siteson
nterminu
gproteincoupl
receptor
also
contain
sequenc
motif
one
second
extracellular
loop
possess
one
nlink
glycosyl
site
third
extracellular
loop
ctermini
molecul
rich
conserv
ser
thr
residu
repres
potenti
phosphoryl
site
famili
gproteincoupl
receptor
kinas
follow
ligand
bind
highli
conserv
cystein
residu
believ
form
disulfid
bond
may
confer
uniqu
barrel
shape
bring
extracellular
domain
closer
proxim
coimmunoprecipit
presenc
lapham
et
al
interact
also
absenc
basmaciogullari
et
al
lapham
et
al
sloan
et
al
also
interact
absenc
hiv
envelop
glycoprotein
rel
low
affinityfor
exampl
affin
constant
nm
measur
interact
express
surfac
neuron
cell
hesselgess
et
al
thu
highaffin
nanomolar
interact
significantli
increas
affin
complex
similar
find
report
bind
cell
presenc
compet
radiolabel
rant
trkola
et
al
wu
et
al
shown
bind
enhanc
solubl
cell
surfaceassoci
measur
inhibit
chemokin
bind
antibodi
epitop
loop
epitop
epitop
well
antibodi
bind
site
lesser
extent
region
prevent
enhanc
effect
absenc
rel
lowaffin
interact
occur
absenc
similarli
associ
lapham
et
al
stauding
et
al
xiao
et
al
cell
line
associ
observ
basmaciogullari
et
al
structur
complex
current
unknown
therefor
exact
local
interact
site
known
howev
number
studi
provid
data
allow
approxim
local
bind
site
identif
longsought
fusion
cofactor
e
berger
associ
feng
et
al
hypothes
form
trimolecular
complex
specul
second
extracellular
loop
like
make
contact
longest
one
like
involv
bind
coreceptor
major
determin
tropism
dimitrov
model
propos
decad
ago
continu
essenti
correct
much
inform
accumul
provid
import
clue
interact
coreceptor
interact
could
inhibit
first
indic
coreceptor
nterminu
import
interact
obtain
studi
first
report
discoveri
fusion
cofactora
polyclon
rabbit
antiserum
nterminu
inhibit
envmedi
fusion
viru
infect
feng
et
al
subsequ
studi
confirm
extend
initi
observ
also
discov
critic
role
coreceptor
second
extracellular
loop
interact
use
chimera
shown
first
amino
acid
nterminu
critic
coreceptor
activ
ntermin
domain
could
confer
coreceptor
function
place
background
rucker
et
al
parallel
studi
obtain
similar
result
util
nterminu
human
murin
background
atchison
et
al
virus
use
coreceptor
also
interact
extracellular
loop
could
toler
substitut
ntermin
domain
correspond
ntermin
domain
diverg
chemokin
receptor
includ
doranz
et
al
rucker
et
al
recent
mab
direct
second
extracellular
loop
detect
longterm
nonprogress
posit
individu
pastori
et
al
loss
antibodi
case
correl
progress
diseas
indic
second
extracellular
loop
possibl
target
inhibitor
vivo
efficaci
chang
individu
residu
result
differ
effect
envmedi
fusion
versu
dualtrop
env
indic
isol
differ
way
interact
restrict
virus
interact
two
bind
site
one
ntermin
domain
one
second
extracellular
loop
dualtrop
env
exhibit
reduc
abil
util
second
extracellular
loop
sensit
mutat
ntermin
domain
doranz
et
al
rucker
et
al
similarli
chimera
chimera
base
examin
abil
support
envmedi
cell
fusion
share
amino
acid
ident
contrast
observ
ntermin
domain
confer
coreceptor
function
picard
et
al
nterminu
could
substitut
correspond
region
still
retain
coreceptor
function
four
five
examin
env
protein
albeit
lower
effici
wildtyp
lower
effici
propos
nterminu
may
contribut
directli
bind
indirectli
promot
conform
favor
interact
particular
env
also
found
role
nterminu
depend
viru
isol
clearli
correl
viru
tropism
note
use
env
tool
identifi
residu
involv
bind
suggest
second
third
extracellular
loop
addit
nterminu
contribut
bind
lin
et
al
studi
show
variant
natur
mutat
describ
variou
human
popul
respond
chemokin
abl
act
coreceptor
effici
express
cell
surfac
bind
affin
similar
blanpain
et
al
addit
mutat
total
unabl
mediat
entri
fact
nonfunct
allel
rel
frequent
variou
human
popul
reinforc
hypothesi
select
pressur
favor
allel
blanpain
et
al
polymorph
chemokin
receptor
gene
implic
hiv
diseas
progress
resist
nonprogress
infect
two
distinct
form
protein
kda
hiv
envelop
glycoprotein
present
human
lymphocyt
cell
monkey
peripher
blood
mononuclear
cell
ratio
two
form
chang
cell
growth
local
studi
indic
resid
mainli
cell
membran
present
sole
cytoplasm
cell
therefor
function
hiv
coreceptor
suzuki
et
al
env
share
function
site
extracellular
domain
recent
data
howev
show
also
four
mutat
second
extracellular
loop
reduc
entri
without
impair
either
ligand
bind
signal
tian
et
al
anoth
studi
show
differ
structur
function
cell
infect
chemotaxi
appar
mediat
differ
isoform
sloan
et
al
comparison
wildtyp
wt
dual
nlink
glycosyl
site
mutant
express
cell
demonstr
variabl
glycosyl
oligomer
almost
half
isoform
immunoprecipit
reveal
monom
dimer
nonglycosyl
form
kda
mutant
compar
glycosyl
kda
kda
form
wt
function
specif
isoform
also
demonstr
fact
differ
isoform
kda
form
found
bind
iiib
env
bind
induc
major
conform
chang
lead
reorgan
structur
element
compris
coreceptor
bind
site
fig
enhanc
bind
coreceptor
coreceptor
bind
induc
addit
conform
chang
transmit
undergo
major
conform
chang
requir
fusion
viral
cell
membran
current
structur
avail
complex
coreceptor
natur
conform
chang
induc
coreceptor
remain
larg
unknown
howev
sever
structur
complex
fragment
avail
thought
play
major
role
conform
chang
caus
merg
viral
plasma
cell
membran
promin
structur
socal
sixhelix
bundl
thought
postfus
structur
result
conform
chang
prehairpin
intermedi
fig
lu
et
al
weissenhorn
et
al
suggest
format
sixhelix
coiledcoil
drive
membran
fusion
markosyan
et
al
melikyan
et
al
although
indic
sixhelix
bundl
could
form
prior
fusion
gold
et
al
parallel
pathway
possibl
involv
gener
monom
coexist
trimer
fusion
process
structur
basi
hiv
entri
mechan
activ
area
research
new
excit
develop
expect
near
futur
infect
hiv
immun
envbas
immunogen
elicit
antibodi
divid
six
major
class
depend
locat
properti
epitop
antibodi
bind
region
contain
antibodi
bind
better
complex
alon
antibodi
carbohydratebind
antibodi
antibodi
antibodi
target
mper
antibodi
bind
epitop
antibodi
isol
specif
hiv
use
variou
strategi
escap
immun
respons
includ
rapid
gener
mutant
outpac
develop
neutral
antibodi
garber
et
al
richman
et
al
wei
et
al
hide
conserv
structur
envelop
glycoprotein
env
import
replic
burton
poignard
et
al
wei
et
al
conserv
structur
hidden
variabl
loop
extens
glycosyl
transient
exposur
occlus
within
oligom
conform
mask
thu
elicit
broadli
crossreact
neutral
antibodi
bcnab
vivo
rare
usual
occur
rel
long
period
matur
burton
montefiori
zollapazn
sever
envspecif
human
monoclon
antibodi
hmab
found
zollapazn
exhibit
neutral
activ
primari
isol
differ
clade
includ
antibodi
roben
et
al
sander
et
al
scanlan
et
al
trkola
et
al
zhang
et
al
cavacini
et
al
gorni
et
al
fab
moulard
et
al
antibodi
muster
et
al
zwick
et
al
fab
recent
sever
novel
hmab
identifi
exhibit
broad
neutral
activ
bind
conform
epitop
distinct
zhang
dimitrov
zhang
et
al
rare
crossreact
antibodi
particular
import
epitop
use
templat
design
vaccin
immunogen
target
inhibitor
antibodi
potenti
therapeut
focu
latest
advanc
hiv
envelop
glycoprotein
understand
antibodi
target
mostli
structur
point
view
epitop
mani
antibodi
character
past
mostli
sitedirect
mutagenesi
competit
bind
focu
two
major
class
antibodi
recogn
receptor
bind
site
antibodi
compet
socal
induc
antibodi
compet
coreceptor
bind
bind
antibodi
typic
enhanc
variou
degre
complex
perhap
bestcharacter
antihiv
antibodi
bind
mani
primari
isol
compet
therefor
epitop
significantli
overlap
structur
determin
biochem
studi
carri
explor
fine
map
interact
mani
mab
includ
pantophlet
et
al
mutagenesi
experi
analysi
structur
identifi
sever
residu
heavi
chain
play
role
bind
uniqu
bind
abil
core
partial
stabil
conform
recent
confirm
crystal
structur
core
complex
kwong
zhou
et
al
addit
structur
crystal
structur
three
antibodi
isol
prabakaran
et
al
wilkinson
et
al
dimitrov
ji
recent
determin
major
structur
featur
antibodi
exist
long
protrud
hydrophob
residu
tip
structur
similar
base
vari
along
torso
tip
region
relat
differ
specif
neutral
activ
fig
thought
long
protrud
antibodi
requir
reach
caviti
howev
recent
determin
structur
stabil
state
core
complex
fab
suggest
actual
contact
caviti
kwong
inde
may
contribut
significantli
contact
area
directli
energi
interact
remain
seen
whether
also
true
antibodi
uniqu
also
aspect
interact
epitop
antibodi
like
share
structur
overlap
howev
exact
local
current
unknown
except
epitop
recent
determin
solv
crystal
structur
complex
stabil
conform
correspond
conform
coreceptor
bind
site
highli
conserv
target
broadli
neutral
antibodi
exact
local
coreceptor
bind
site
known
lack
crystal
structur
complex
coreceptor
extens
mutagenesi
studi
allow
locat
around
bridg
sheet
fig
prior
bind
element
contribut
bind
site
dispers
surfac
fig
mask
variabl
loop
therefor
easili
access
neutral
antibodi
conform
chang
lead
format
coreceptor
bind
site
enhanc
bind
antibodi
typic
compet
coreceptor
bind
number
antibodi
includ
recogn
highli
conserv
epitop
overlap
variou
extent
coreceptor
bind
site
epitop
known
determin
structur
complex
fab
fab
fig
epitop
overlap
significantli
coreceptor
bind
site
long
domin
bind
residu
light
chain
also
contribut
fig
antibodyantigen
interfac
interact
buri
epitop
span
across
fourstrand
bridg
sheet
fig
hydrophob
core
flank
basic
residu
although
paratop
highli
acid
make
signific
salt
bridg
basic
residu
complex
structur
larg
gap
seen
base
tip
light
chain
appear
rigid
seen
minor
chang
free
bound
kwong
et
al
structur
fig
importantli
epitop
well
conserv
among
sever
isol
contact
residu
residu
conserv
among
isol
kwong
et
al
potent
broadli
neutral
fab
select
immung
phage
display
antibodi
librari
bind
highaffin
primari
isol
differ
clade
even
absenc
howev
bind
significantli
increas
presenc
moulard
et
al
similar
contact
sever
residu
bridg
sheet
also
residu
region
highli
conserv
fig
tabl
notabl
highli
conserv
residu
previous
identifi
hotspot
darbha
et
al
show
loss
solventaccess
area
contact
contrast
undergo
larg
conform
chang
bind
maximum
displac
c
posit
fig
one
largest
induc
fit
ever
observ
antibodi
util
flexibl
loop
buri
solventaccess
area
bind
correspond
loss
long
residu
form
epitop
highli
conserv
shown
asterisk
mutat
site
similar
amino
acid
shown
colon
highli
flexibl
may
toler
lessconserv
contact
residu
exampl
time
make
tight
bind
function
hotspot
residu
exampl
facilit
induc
fit
perhap
might
contribut
broad
potent
neutral
abil
tabl
show
list
differ
isol
three
major
clade
ac
potent
neutral
antibodi
along
align
epitop
residu
residu
bind
highli
conserv
expos
mark
asterisk
buri
surfac
area
bottom
epitop
residu
tabl
long
residu
contain
four
glycin
sever
charg
mainli
acid
asp
residu
hydrophob
residu
could
reach
part
epitop
hidden
steric
restrict
nonneutr
antibodi
acid
surfac
may
mimic
acid
ntermin
portion
necessari
bind
exhibit
similar
acid
properti
due
three
asp
three
glu
residu
epitop
residu
posit
basic
compens
acid
surfac
also
form
strong
salt
bridg
conserv
make
direct
salt
bridg
residu
respect
donoracceptor
distanc
rang
lessconserv
side
chain
contact
carbonyl
group
bulki
perfect
candid
make
polar
charg
stack
interact
lysglnarg
residu
posit
though
also
acid
salt
bridg
made
residu
addit
signific
role
glycin
residu
explor
molecular
dynam
simul
glycin
residu
found
contribut
flexibl
taken
togeth
appear
uniqu
mechan
level
bind
activ
among
known
antibodi
figur
clearli
show
long
reach
epitop
altern
antibodi
bind
mechan
expos
receptor
bind
site
sar
coronaviru
recent
demonstr
antigen
combin
site
antisar
fab
form
canyon
interact
expos
part
receptor
bind
site
fig
appear
bind
bind
site
mechan
similar
fab
fab
neutral
activ
antibodi
could
significantli
reduc
steric
restrict
access
epitop
conserv
discontinu
segment
overlap
coreceptorbind
site
recogn
mab
effici
bind
bind
dock
receptor
site
space
need
antibodi
bind
epitop
significantli
reduc
found
size
restrict
effect
lead
invers
correl
antibodi
neutral
activ
size
labrijn
et
al
shown
fig
avail
space
epitop
target
cell
membran
attach
estim
highest
dimens
labrijn
et
al
compar
dimens
differ
format
antibodi
igg
fab
scfv
shown
fig
antibodi
fragment
either
fab
scfv
effect
whole
igg
antibodi
molecul
get
restrict
bind
site
need
neutral
howev
note
factor
includ
avid
effect
due
bival
could
contribut
bind
exampl
case
potent
neutral
isol
scfv
labrijn
et
al
vivo
could
much
greater
neutral
activ
due
effector
function
fc
two
promin
antibodi
isol
almost
two
decad
ago
h
kating
associ
ebv
immort
b
lymphocyt
individu
averag
appear
potent
exhibit
broader
neutral
activ
test
cell
linepseudoviru
assay
binley
et
al
recogn
almost
contigu
adjac
segment
eldkwa
nwf
dn
respect
trprich
environ
mper
fig
peptid
aa
contain
eldkwa
region
near
ctermin
region
peptid
play
essenti
role
fusogen
structur
format
potent
inhibitor
hiv
infect
patient
current
entri
inhibitor
clinic
use
mper
includ
epitop
highli
conserv
mutat
hydrophob
residu
region
larg
affect
viral
entri
howev
attempt
use
mper
elicit
antibodi
met
limit
success
understand
better
interact
antibodi
epitop
could
provid
clue
develop
effect
vaccin
immunogen
crystal
structur
ofek
et
al
cardoso
et
al
complex
peptid
mper
determin
structur
discuss
detail
crystal
structur
complex
peptid
shown
fig
surfac
represent
ofek
et
al
peptid
residu
lie
cdr
interfac
heavi
light
chain
rel
extend
conform
span
around
hiv
envelop
glycoprotein
measur
lead
residu
disord
structur
two
three
turn
peptid
belong
type
bturn
overlap
interestingli
three
intrapeptid
hydrogen
bond
constrain
conform
six
residu
total
surfac
peptid
buri
peptid
interact
typic
antibodyantigen
interact
residu
except
directli
bind
antibodi
strikingli
contact
region
restrict
cdr
also
includ
nonpolymorph
region
nterminu
light
chain
bind
site
peptid
one
exclus
face
account
total
peptid
area
avail
bind
indic
unbound
part
may
interact
portion
env
analysi
peptid
surfac
reveal
two
major
region
one
region
bound
charg
region
occlud
hydrophob
latter
properti
surfac
suggest
possibl
proteinprotein
interact
occlud
bind
failur
elicit
antibodi
peptid
may
relat
lack
appropri
occlus
anoth
hint
mechan
bind
infer
form
bind
mode
length
amino
acid
length
antibodi
unlik
fab
make
contact
tip
base
fig
shown
green
tip
sever
hydrophob
residu
present
protrud
flat
surfac
surfac
align
hydrophob
indol
side
chain
termin
residu
peptid
arrang
involv
peptid
termin
residu
hydrophob
plane
indic
possibl
apex
could
interact
directli
viral
membran
accommod
recogn
epitop
closer
membran
proxim
region
agreement
biochem
nmr
studi
appear
epitop
rel
flexibl
probabl
assum
differ
conform
depend
state
interestingli
evid
access
restrict
due
size
interact
peptid
contain
sequenc
nwfdit
topolog
similar
epitop
differ
detail
cardoso
et
al
fig
peptid
helic
conform
contrast
peptid
similar
peptid
structur
trprich
mper
determin
nmr
key
residu
appear
one
side
helix
render
hydrophob
surfac
interact
antibodi
residu
use
side
chain
plung
hydrophob
pocket
creat
cdr
antibodycombin
site
total
surfac
buri
peptid
respect
bind
make
contact
tip
simila
rli
fig
c
case
indic
possibl
tip
contact
viral
membran
portion
ectodomain
intact
viru
agreement
possibl
biochem
analysi
use
env
proteoliposom
demonstr
enhanc
bind
presenc
lipid
membran
ofek
et
al
interest
featur
five
glycin
long
could
certainli
contribut
flexibl
may
requir
epitop
recognit
particularli
two
tryptophan
residu
tip
posit
reach
membran
result
suggest
conserv
steric
constrainsfre
region
avail
potenti
epitop
exampl
epitop
two
antibodi
share
structur
featur
interact
pattern
core
epitop
also
specif
featur
relat
distinct
epitop
use
inform
mper
structur
part
epitop
design
effect
vaccin
immunogen
remain
seen
recent
six
novel
hmab
identifi
exhibit
broad
neutral
activ
bind
conform
epitop
distinct
zhang
dimitrov
zhang
et
al
compet
significantli
indic
local
epitop
like
outsid
mper
conserv
structur
contain
epitop
character
conserv
structur
contigu
segment
includ
bhairpin
rigid
motif
prompt
ration
design
mimic
could
block
hiv
entri
huang
et
al
martin
et
al
vita
et
al
zhang
et
al
bind
interact
mainli
involv
contigu
segment
render
residu
contribut
bhairpin
region
contain
hotspot
acid
long
mimic
specif
initi
design
graft
major
contributor
compon
loop
major
hotspot
small
structur
scaffold
stabil
disulfid
bond
scorpion
toxin
charybdotoxin
drakopoul
et
al
later
protein
call
amino
acid
use
scyllatoxin
scaffold
design
threedimens
structur
solv
nmr
vita
et
al
base
structur
inform
deriv
complex
miniprotein
design
applic
possibl
therapeut
test
determin
sever
hiv
envelop
glycoprotein
thermodynam
neutral
paramet
nmr
structur
show
welldefin
bhairpin
phenylalanin
residu
posit
equival
region
appear
retain
conserv
interact
dock
complex
final
crystal
structur
analogu
complex
determin
extent
molecular
mimicri
neutral
breadth
analyz
huang
et
al
spite
highli
flexibl
envelop
conform
mimic
complex
similar
induc
fig
interestingli
bhairpin
engag
hydrogen
bond
strand
similar
way
demonstr
success
attempt
graft
bind
interfac
smaller
scaffold
thermodynam
character
bind
mimic
show
half
associ
entrop
chang
occur
compar
bind
nonetheless
mimic
induc
conform
chang
requir
enhanc
bind
differ
mimic
phenyl
ring
replac
biphenyl
side
chain
residu
substitut
significantli
enhanc
structur
mimicri
specif
posit
huang
et
al
success
structur
mimicri
miniprotein
prompt
research
attempt
design
nativ
mimic
greater
antivir
activ
hiv
giant
struggl
hiv
immun
system
antibodi
uniqu
properti
evolv
mimic
coreceptor
induc
conform
chang
receptor
could
lead
enhanc
infect
addit
bind
first
domain
similar
v
domain
antibodi
exampl
comparison
domain
vh
domain
shown
fig
b
molecular
view
gener
translat
superposit
two
molecul
base
disulfid
bridg
locat
residu
posit
label
fig
found
criticala
point
mutat
greatli
diminish
bind
base
footprint
data
two
finger
specul
occupi
hydrophob
pocket
surfac
sinc
equival
c
c
region
could
use
receptor
mimic
protein
engin
fab
anoth
antibodi
broad
neutral
activ
recent
identifi
crystal
structur
solv
prabakaran
et
al
vh
domain
compar
shown
fig
remark
featur
antibodi
structur
highli
resembl
part
fig
adopt
bhairpin
form
rigid
structur
crosslink
hydrogen
bond
throughout
torso
region
importantli
phe
residu
posit
analog
hotspot
loop
unexpect
structur
hiv
envelop
glycoprotein
similar
includ
hotspot
phe
residu
robust
bsheet
featur
observ
fig
suggest
possibl
protein
graft
mimic
c
c
might
provid
use
strategi
develop
antibodybas
mimet
inhibit
hiv
entri
antibodi
mimic
also
antibodi
mostli
bind
coreceptor
bind
site
mimic
certain
featur
hiv
coreceptor
unlik
case
mimic
structur
avail
coreceptor
howev
crystal
structur
sever
fab
solv
reveal
mechan
atomiclevel
detail
three
interest
featur
posttransl
mimicri
coreceptor
tyrosin
sulfat
antibodi
altern
molecular
mechan
control
sulfat
highli
select
v
h
gene
usag
choe
et
al
huang
et
al
anoth
demonstr
adapt
capabl
immun
system
confront
extraordinari
viral
defens
develop
effect
vaccin
hiv
intern
public
health
prioriti
role
hiv
envelop
play
infect
make
primari
target
effort
multitud
approach
attempt
eloqu
summar
numer
recent
review
dsouza
et
al
duerr
et
al
koff
et
al
letvin
mcmichael
singh
et
al
slobod
et
al
spearman
wang
work
clearli
possibl
creat
vaccin
induc
cellular
respons
protect
diseas
progress
suppress
viral
load
infect
occur
howev
none
abl
achiev
penultim
goal
prevent
infect
entir
goal
requir
envbas
vaccin
induc
protect
antibodi
respons
summar
prevail
approach
use
env
elicit
broadli
neutral
antibodi
epitop
target
inhibitor
special
emphasi
common
challeng
guid
principl
current
hiv
vaccin
effort
antibodi
neutral
hiv
vitro
protect
anim
hiv
infect
vivo
principl
base
three
observ
expand
number
passiv
challeng
studi
macaqu
treat
mab
pool
hightit
antisera
neutral
vitro
protect
cellfre
shiv
viru
challeng
baba
et
al
emini
et
al
ferrantelli
et
al
ferrantelli
et
al
hofmannlehmann
et
al
b
mascola
et
al
mascola
et
al
mascola
et
al
nishimura
et
al
putkonen
et
al
ruprecht
et
al
shibata
et
al
van
rompay
et
al
zhang
et
al
antibodi
demonstr
best
efficaci
hivig
strong
cellular
respons
enhanc
protect
shiv
challeng
provid
passiv
transfer
antibodi
mascola
et
al
ii
second
natur
infect
autolog
neutral
respons
exert
select
pressur
hiv
evolut
vivo
albert
et
al
arendrup
et
al
bradney
et
al
eichberg
et
al
montefiori
et
al
parren
et
al
reitz
et
al
richman
et
al
watkin
et
al
wei
et
al
hiv
evad
select
pressur
sever
mechan
introduc
new
nlink
glycosyl
residu
present
protect
glycan
shield
back
et
al
chackerian
et
al
derdeyn
et
al
kolchinski
et
al
quinoneskoch
et
al
reitter
et
al
wei
et
al
conform
entrop
mask
vulner
epitop
shed
monomer
envelop
protein
enhanc
domin
nonneutr
epitop
burton
montefiori
simpl
epitop
variat
discourag
antibodi
control
infect
observ
hiv
evad
antibodi
suggest
impact
iii
longterm
nonprogress
associ
presenc
hightit
broadli
neutral
respons
cao
et
al
cecilia
et
al
hutto
et
al
kloosterbo
et
al
pilgrim
et
al
scarlatti
et
al
zhang
et
al
although
other
postul
connect
tenuou
montefiori
et
al
direct
link
level
neutral
antibodi
diseas
progress
establish
cecilia
et
al
recent
studi
connect
evas
neutral
suggest
perhap
antibodi
respons
patient
may
better
abl
contain
viru
long
term
base
observ
easi
conclud
vaccin
stimul
neutral
respons
would
highli
desir
thu
signific
effort
direct
develop
immunogen
induc
antibodi
broadli
neutral
specif
antibodi
score
posit
vitro
neutral
assay
mediat
protect
vivo
howev
antibodi
score
neg
assay
effect
literatur
suggest
signific
subset
bind
nonneutr
antibodi
impact
hiv
diseas
progress
possibl
even
transmiss
bindingnonneutr
hiv
envelop
glycoprotein
antibodi
viru
surfac
glycoprotein
shown
protect
infect
viru
system
includ
sindbi
viru
stanley
et
al
venezuelan
equin
encephalomyel
viru
mathew
roehrig
herpesviru
dix
et
al
vesicular
stomat
viru
lefrancoi
hiv
compel
evid
nonneutr
protect
antibodi
come
test
dnamva
vaccin
macaqu
vaccin
contain
pol
gag
env
sequenc
encod
first
amino
acid
residu
ada
envelop
afford
stronger
protect
mucos
shiv
challeng
match
vaccin
contain
gag
pol
amara
et
al
sinc
effect
vaccin
contain
env
rais
neutral
antibodi
challeng
viru
enhanc
protect
attribut
high
titer
antienvelop
bind
antibodi
recent
macaqu
studi
show
viral
contain
immun
preserv
confer
dna
adenoviru
vaccin
significantli
enhanc
inclus
chimer
sequenc
heterolog
respect
challeng
shiv
letvin
et
al
although
investig
attribut
protect
crossreact
cellular
respons
rais
conserv
hiv
envelop
sequenc
studi
rule
role
nonneutr
antibodi
sum
nonneutr
antibodi
appear
protect
diseas
via
mechan
overlook
convent
vitro
viral
neutral
assay
common
mechan
attribut
nonneutr
control
fc
receptormedi
complementmedi
inhibitori
cytolyt
activ
instanc
antibodydepend
cellmedi
cytotox
adcc
review
ahmad
menez
gomezroman
et
al
associ
improv
control
viremia
count
hivinfect
patient
ahmad
et
al
forthal
et
al
forthal
et
al
slower
diseas
progress
sivinfect
macaqu
bank
et
al
one
recent
studi
observ
correl
adcc
activ
reduc
viral
load
rhesu
macaqu
mucos
challeng
siv
fcmediat
effector
mechan
also
attribut
enhanc
neutral
efficaci
serum
observ
mdm
immatur
dendrit
cell
idc
use
cellular
target
instead
activ
pbmc
holl
et
al
holl
et
al
fact
mab
present
minim
neutral
activ
pbmcbase
assay
highli
inhibitori
mdmor
idcbas
assay
holl
et
al
mab
recogn
portion
nativ
envelop
spike
expos
dead
spike
express
nativ
virion
unabl
mediat
fusion
uncleav
lost
portion
moor
et
al
zanetti
et
al
zhu
et
al
nonneutr
antibodi
may
impact
hiv
transmiss
remain
unansw
although
clearcut
protect
mechan
nonneutr
antihiv
antibodi
establish
nevertheless
prudent
consid
envbas
vaccin
candid
may
stimul
inhibitori
activ
humor
respons
epitop
expos
viral
entri
may
provid
new
opportun
vaccin
develop
respons
warrant
attent
recogn
conserv
function
import
region
hiv
envelop
question
hand
whether
respons
antigen
rais
worth
pursu
vaccin
unfortun
view
epitop
vaccin
target
color
recent
find
discuss
use
comput
model
base
crystal
structur
suggest
epitop
actual
occlud
entri
labrijn
et
al
support
model
gener
show
recogn
epitop
profoundli
less
effect
smaller
fab
scfv
fragment
antibodi
neutral
small
panel
primari
use
isol
labrijn
et
al
howev
isol
potent
smaller
fragment
like
due
avid
effect
bival
addit
neutral
activ
antibodi
epitop
depend
assay
condit
found
differ
level
express
tzmbl
cell
line
commonli
use
neutral
assay
pha
acti
vate
pbmc
choud
hri
et
al
platt
et
al
platt
et
al
shown
entri
kinet
isol
exquisit
sensit
level
express
target
cell
fact
use
artifici
cell
line
target
demonstr
virus
becom
increasingli
suscept
entri
inhibitor
level
drop
moleculescel
binley
et
al
emphas
point
show
neutral
efficaci
fab
significantli
improv
pbmcbase
neutral
assay
compar
cell
linebas
assay
known
much
express
cell
initi
target
hiv
numer
studi
determin
express
level
variou
mucos
lymphoid
tissu
significantli
lower
per
cell
well
rang
antibodi
may
effect
clear
epitop
rais
hiv
infect
sinc
hmab
recogn
epitop
coreceptor
bind
site
deriv
person
robinson
et
al
xiang
et
al
last
year
report
decker
et
al
sera
hivinfect
person
contain
antibodi
extrem
potent
crossreact
presenc
small
amount
presum
hiv
envelop
glycoprotein
stabil
exposur
epitop
shown
titer
broadli
neutral
antibodi
detect
neutral
assay
correl
strongli
abil
sera
block
bind
biotinyl
human
mab
epitop
complex
elisa
find
led
percept
hightitt
respons
epitop
found
hivinfect
person
therefor
meaningless
irrelev
vaccin
design
unfortun
percept
may
misinterpret
result
first
demonstr
increas
neutral
potenc
observ
serum
presenc
decker
et
al
also
show
sera
compet
mab
bind
complex
use
assay
test
percentag
block
singl
dilut
serum
assay
howev
demonstr
presenc
high
bind
titer
antibodi
second
propos
respons
highli
conserv
domain
may
constrain
breadth
viral
quasispeci
occur
natur
infect
drive
evolut
viru
protect
epitop
decker
et
al
hypothesi
consist
observ
infect
rhesu
macaqu
neutral
sensit
mildli
pathogen
strain
becom
resist
highli
pathogen
part
introduc
nand
olink
glycosyl
residu
region
occlud
coreceptor
bind
chackerian
et
al
kimata
et
al
b
percept
also
beg
question
whether
lead
vaccin
candid
intend
target
respons
domain
abandon
given
evid
respons
direct
highli
preval
hiv
infect
associ
progress
aid
hioe
et
al
antibodi
also
shown
inhibit
antigen
present
hioe
et
al
hioe
et
al
tuen
et
al
would
argu
absenc
welldesign
safeti
anim
protect
studi
would
exclud
one
epitop
anoth
prudent
consid
immunogen
design
effect
respons
toward
epitop
therefor
reason
propos
test
whether
preexist
humor
mucos
respons
direct
epitop
could
afford
protect
primat
lentivir
infect
sever
indirect
observ
literatur
suggest
answer
ye
infect
macaqu
macrophag
tropic
siv
strain
luciw
et
al
puffer
et
al
lead
transient
attenu
viremia
isol
gener
potent
neutral
respons
may
role
control
observ
viremia
protect
gener
observ
subsequ
challeng
infect
macaqu
highli
pathogen
siv
strain
ii
siv
strain
defici
either
variabl
loop
specif
glycosyl
site
occlud
coreceptor
interact
domain
siv
spike
protein
independ
highli
suscept
neutral
siv
immun
sera
mab
recogn
epitop
johnson
et
al
attenu
version
siv
isol
induc
antibodi
respons
capabl
neutral
neutral
resist
vitro
reitter
et
al
protect
challeng
mori
et
al
iii
protect
cohort
individu
expos
hiv
remain
uninfect
associ
presenc
mucos
serum
antibodi
hiv
studi
exhibit
neutral
activ
one
cohort
protect
associ
antibodi
titer
epitop
express
complex
hivspecif
cell
respons
nguyen
et
al
iv
passiv
protect
studi
delin
clear
correl
neutral
efficaci
antibodi
vitro
abil
passiv
protect
shiv
challeng
vivo
formul
polyclon
hivig
contain
antibodi
epitop
among
other
demonstr
protect
efficaci
vagin
challeng
similar
infus
mixtur
mascola
et
al
despit
observ
formul
demonstr
equival
neutral
titer
vitro
addit
appear
fit
transmiss
enhanc
viru
expressesexpos
coreceptor
bind
domain
viral
spike
taken
togeth
believ
preponder
evid
suggest
vaccin
target
epitop
may
provid
level
protect
transmit
viru
logic
coincid
ongo
vaccin
develop
effort
field
daunt
part
challeng
evas
power
provid
sequenc
divers
env
quickli
appar
standard
vaccin
approach
use
kill
viru
solubl
monomer
immunogen
gener
typespecif
immun
neutral
sourc
viru
immunogen
close
rel
today
effort
identifi
immunogen
immun
strategi
induc
antibodi
respons
exhibit
broader
neutral
andor
protect
phenotyp
immunogen
approach
group
two
broad
overlap
categori
base
whether
respect
antibodi
target
epitop
virion
spike
epitop
appear
entri
five
broadli
neutral
antibodi
recogn
conserv
epitop
express
viral
spike
bind
receptor
lead
investig
suggest
optim
vaccin
candid
induc
antibodi
preferenti
bind
viral
spike
fout
et
al
effort
reach
goal
focus
follow
approach
ad
remov
asn
residu
alter
level
nlink
glycosyl
shield
expos
deep
pocket
hope
result
immunogen
induc
broadli
neutral
antibodi
like
koch
et
al
ii
express
outer
domain
yang
et
al
outer
domain
expos
envelop
spike
contain
bind
surfac
broadli
neutral
loop
antibodi
iii
express
solubl
form
oligomer
envelop
trimer
mimic
spike
appear
hiv
virion
typic
investig
express
protein
fusion
ectodomain
review
cho
construct
typic
gener
prepar
consist
mixtur
monomer
oligomer
form
recent
effort
improv
consist
yield
trimer
form
introduc
disulfid
link
proxim
domain
call
so
sosip
envelop
beddow
et
al
binley
et
al
use
envelop
gene
deriv
hiv
strain
highli
stabl
spike
lian
et
al
sharma
et
al
srivastava
et
al
zhang
et
al
creat
hivsiv
envelop
chimera
center
et
al
fuse
envelop
ectodomain
nonhiv
sequenc
preferenti
form
trimer
pancera
et
al
yang
et
al
yang
et
al
effort
produc
solubl
spike
antigen
profil
consist
nativ
virion
investig
produc
so
sosip
variant
cell
line
overexpress
furin
proteas
cleav
fusion
respect
domain
iv
minim
conform
entrop
mask
conserv
neutral
domain
introduc
mutat
restrain
movement
xiang
et
al
concept
deriv
studi
show
bind
broadli
neutral
antibodi
consist
realiz
minim
entrop
chang
contrast
sharpli
less
effect
antibodi
gener
significantli
larger
entrop
chang
given
rang
movement
possibl
inner
outer
domain
envelop
indic
crystal
structur
propos
viru
may
evad
neutral
use
entrop
mask
conform
barrier
antibodi
must
overcom
actual
bind
introduc
mutat
limit
movement
replac
tryptophan
serin
posit
reduc
entrop
requir
antibodi
bind
may
improv
chanc
induc
prefer
antibodi
specif
v
mimick
highmannosetyp
oligosaccharid
present
hiv
envelop
recogn
review
wang
recent
construct
describ
mimic
bind
site
use
organ
scaffold
decor
synthet
oligomannos
structur
structur
recogn
vari
degre
immunogen
construct
describ
vi
mimick
mper
envelop
spike
recogn
review
zwick
recent
appreci
lipid
membran
hydrophob
context
epitop
critic
antibodi
bind
hayn
et
al
observ
may
explain
dearth
success
use
peptidebas
mimic
eptiop
induc
respons
rejuven
effort
develop
new
mimic
sever
novel
construct
present
brunel
et
al
luo
et
al
howev
immunogen
data
limit
unfortun
evalu
immunogen
strategi
describ
typic
fail
elicit
antibodi
capabl
neutral
minor
fraction
primari
isol
beddow
et
al
graham
selvarajah
et
al
make
matter
wors
recent
hypothes
b
cell
respond
mper
epitop
delet
lipid
portion
target
epitop
consid
self
hayn
et
al
hypothesi
would
explain
respons
infrequ
observ
also
suggest
induct
respons
direct
mper
may
requir
immunogen
capabl
break
one
natur
toler
cell
membran
whether
recogn
similarli
toler
epitop
unclear
certainli
design
vaccin
immunogen
would
target
respons
epitop
repres
daunt
immunolog
structur
potenti
regulatori
challeng
summar
earlier
coreceptorbind
domain
structur
highli
conserv
among
hiv
siv
prompt
investig
develop
immunogen
induc
antibodi
target
structur
one
immunogen
complex
form
viru
attach
cell
surfac
receptor
studi
mice
goat
recent
rhesu
macaqu
shown
broadli
neutral
antibodi
respons
elicit
immun
variou
form
complex
bower
et
al
celada
et
al
devico
et
al
fout
et
al
gershoni
et
al
kang
et
al
three
group
immunogen
develop
attempt
repres
hiv
envelop
glycoprotein
complex
first
group
consist
complex
solubl
envelop
protein
subunit
solubl
human
bower
et
al
celada
et
al
devico
et
al
fout
et
al
fout
et
al
gershoni
et
al
et
al
varadarajan
et
al
immunogen
produc
simpli
mix
two
solubl
compon
togeth
allow
bind
form
complex
express
genet
tether
chimer
molecul
exampl
chimera
fulllength
singl
chain
flsc
genet
fusion
bal
domain
fout
et
al
second
group
consist
solubl
envelop
protein
complex
human
mab
liao
et
al
bind
epitop
defin
region
hiv
envelop
subunit
like
known
induc
express
coreceptor
bind
domain
within
liao
et
al
wyatt
et
al
complex
produc
admix
two
compon
allow
bind
solut
form
complex
liao
et
al
third
complex
mimic
peptid
fout
et
al
varadarajan
et
al
vita
et
al
unfortun
affin
insuffici
permit
format
stabl
complex
solut
two
compon
vita
et
al
stabl
complex
express
howev
chimer
fusion
protein
fout
et
al
varadarajan
et
al
bal
jrfl
respect
genet
tether
short
amino
acid
linker
stabl
complex
also
creat
use
martin
et
al
modifi
exhibit
affin
closer
huang
et
al
presumpt
complex
exhibit
antigen
featur
present
hiv
envelop
spike
interact
cell
surfac
thu
far
admix
crosslink
complex
shown
elicit
neutral
antibodi
respons
other
still
evalu
whether
result
neutral
respons
aris
exposur
cryptic
epitop
either
enhanc
immunogen
alter
immunogen
extant
epitop
celada
et
al
devico
et
al
still
unclear
either
instanc
would
enhanc
potenti
complex
elicit
broadli
crossreact
antibodi
three
recent
studi
gener
rather
differ
result
use
variou
form
complex
immunogen
et
al
liao
et
al
varadarajan
et
al
howev
studi
suffer
one
either
two
major
flaw
first
evalu
immunogen
construct
anim
model
mice
guinea
pig
heterolog
moieti
use
immunogen
human
known
sinc
first
studi
complex
appear
substanti
level
antibodi
elicit
use
complex
speci
ie
human
differ
one
ie
rodent
immun
celada
et
al
human
highli
immunogen
rodent
bias
respons
complex
away
conserv
epitop
obscur
immunogen
properti
constrain
hiv
envelop
moieti
favor
respons
said
two
independ
report
bower
et
al
srivastava
et
al
includ
one
singlechain
immunogen
test
mice
bower
et
al
show
broadli
neutral
antibodi
fraction
isol
anim
immun
heterolog
complex
recogn
second
immunogen
truli
mimic
structur
present
complex
use
one
studi
liao
et
al
use
conform
constrain
mab
immunogen
propos
bind
way
mimic
judg
exposur
epitop
recogn
mab
wyatt
et
al
guinea
pig
immun
coval
conjug
bal
mount
neutral
antibodi
respons
larg
indistinguish
elicit
bal
alon
found
conform
chang
induc
distinct
judg
differenti
reactiv
antibodi
recogn
epitop
bridg
sheet
envelop
fout
et
al
unpublish
data
notabl
serum
antibodi
respons
epitop
thought
constrain
viral
divers
vivo
decker
et
al
observ
may
explain
bal
complex
elicit
differ
pattern
reactiv
complex
approach
also
util
target
epitop
common
remov
hypervari
andor
region
envelop
primari
target
typespecif
antibodi
respons
shield
conserv
neutral
epitop
review
cho
recent
investig
develop
construct
deriv
envelop
sequenc
isol
adapt
grow
cell
line
devoid
hoffman
et
al
kolchinski
et
al
isol
patient
high
level
broadli
neutral
antibodi
quinnan
et
al
vujcic
quinnan
zhang
et
al
envelop
contain
structur
alter
provid
recept
interact
coreceptor
fewer
nlink
glycosyl
shift
loop
full
spectrum
potenti
epitop
recent
becom
appar
difficult
argu
epitop
poor
target
vaccin
develop
labrijn
et
al
addit
known
whether
mab
specif
epitop
protect
passiv
transfer
studi
rhesu
macaqu
regard
passiv
transfer
studi
hiv
envelop
glycoprotein
carri
use
mixtur
mab
specif
epitop
shown
neg
prematur
exclud
strategi
base
vitro
neutral
data
alon
also
recogn
immun
complex
dramat
chang
immunodomin
profil
de
ni
sov
et
al
fout
et
al
kang
et
al
fout
et
al
unpublish
data
possibl
lead
immunogen
previous
silent
epitop
elicit
protect
respons
vivo
entri
process
hiv
also
prime
target
thera
peuti
cs
ea
rli
eff
ort
interf
entri
utili
zed
polyclo
nal
antibo
dy
prepa
ration
devel
ope
hiv
patient
hi
vig
mab
exh
ibit
ex
ception
neutralizi
ng
capac
vitro
review
choud
hri
et
al
unf
ortunat
eli
prepara
tion
provid
much
way
thera
peutic
utili
ty
despit
safe
ty
wh
en
impact
vira
l
load
effect
tran
ient
resistan
viru
es
quickl
eme
rging
key
br
eakthro
ugh
came
licensur
e
enfuvi
rtide
target
review
weiss
drug
first
cla
reach
mark
tpla
ce
foref
ront
armi
inhi
bitor
make
way
clinic
de
velop
drug
genera
lli
fall
within
four
broad
group
devel
ope
thera
peutic
vagina
lli
rectal
appli
microbi
cidal
indic
antibod
i
given
safe
ty
recor
clinic
developm
nt
antibodi
hiv
thera
py
con
tinu
promisi
ng
new
cand
idat
targ
ccr
att
mpting
minim
ize
chanc
evas
targeti
ng
cel
lular
recep
tor
inst
ead
envel
ope
dimit
rov
ii
peptid
group
populat
ed
fuz
eon
vari
eti
follo
candid
target
helic
region
main
challeng
group
deliveri
fuzeon
requir
intramuscular
administr
twice
daili
make
rather
unfavor
choic
patient
newer
deliveri
method
formul
develop
may
help
solv
problem
markov
pierson
dom
b
iii
lectin
varieti
lectin
shown
inhibit
hiv
bind
mannos
structur
cover
envelop
spike
drug
current
develop
vagin
rectal
use
microbicid
howev
potenti
therapeut
util
de
pierson
dom
cyanovirin
cvn
current
furthest
clinic
develop
iv
small
compound
group
bulk
new
inhibitor
fall
thu
far
maraviroc
small
molecul
antagonist
target
reach
phase
iii
group
drug
prove
highli
effect
reduc
viral
load
fall
develop
varieti
safeti
problem
de
kadow
et
al
markov
pierson
dom
drug
respect
target
eloqu
describ
mani
recent
review
cite
given
wealth
research
direct
understand
nuanc
hiv
entri
anticip
pipelin
drug
candid
dri
anytim
soon
vii
conclus
hiv
evolv
number
strategi
escap
host
immun
surveil
promin
modif
env
latest
advanc
understand
structur
atom
level
detail
promis
provid
us
new
tool
design
effect
vaccin
inhibitor
spite
signific
progress
contribut
develop
vaccin
therapeut
wealth
inform
env
structur
still
rel
small
howev
current
develop
promis
revolution
way
therapeut
vaccin
design
futur
remain
seen
whether
promis
materi
